Arm lymphoscintigraphy after axillary lymph node dissection or sentinel lymph node biopsy in breast cancer

Periclavicular Lymph Node Activation Maintains the Lymphatic Circulation of Upper Extremity Following Breast Cancer Surgery with Axillary Lymph Node Dissection

Backgrounds: Axillary lymph node dissection (ALND) can cause breast cancer-related lymphedema (BCRL). However, ALND does not always produce lymphedema to the breast cancer survivors. Therefore, we aimed to investigate the correlation between the finding of lymphoscintigraphy and lymphedema in patients undergoing breast cancer surgery with ALND. Methods and Results: Patients with BCRL (n = 73, mean age: 53.92 ± 11.13 years) after full ALND (levels I, II, and III) were retrospectively included in this study. All patients underwent lymphoscintigraphy and according to the findings of the imaging, patients were divided into three groups: negative group, periclavicular lymph nodes (P-LN) activation, and axillary lymph nodes (A-LN) activation. According to the extent of radiation therapy, groups were classified as the following: no radiation group (None), breast radiation group (BI), and breast irradiation in addition to P-LN (BI+PC). The percentage difference in the upper extremities was used as the marker of severity of lymphedema. The subjects in the negative group, P-LN, and A-LN were 34 (46.6%), 33 (45.2%), and 6 (8.2%) patients, respectively. The findings of lymphangiography showed statistically significant relationship with the severity of lymphedema. The extent of radiation therapy did not have statistically significant relationship. Despite ALND, 53.4% patients had active L/N capable of removing the upper limb lymphatic fluids and 45.2% patients showed activation of collateral formation of lymphatic circulation after ALND. Conclusion: The collateral lymphatic formation was provoked after breast cancer operation with ALND, which decreased the severity of lymphedema in breast cancer survivors.

Ultrasound Features of Breast Cancer for Predicting Axillary Lymph Node Metastasis

OBJECTIVES

The purpose of this study was to assess the clinical value of ultrasound (US) features of breast lesions for predicting the risk of axillary lymph node metastasis in patients with breast cancer.

METHODS

In this retrospective study, 425 patients with breast cancer were recruited, and their preoperative US features and postoperative pathologic results were collected. The association of these US features of breast cancer with axillary lymph node metastasis was determined by univariate and multivariate analyses.

RESULTS

Among the 425 patients, 200 (47.1%) had axillary lymph node metastasis, and 225 (52.9%) did not. The parameters of tumor shape, color Doppler flow imaging grades, histologic grade, and E-cadherin level were significantly and independently associated with axillary lymph node metastasis (P < .05 for all).

CONCLUSIONS

Axillary lymph node metastasis was prone to happen in patients with US features of an irregular tumor shape and higher color Doppler flow imaging grades. Ultrasound imaging provides a promising tool for predicting axillary lymph node metastasis in patients with breast cancer.

[Not Available]

Zusammenfassung. Das Lymphödem ist eine häufige, chronisch fortschreitende und potenziell invalidisierende Erkrankung. In den entwickelten Ländern ist das Extremitätenlymphödem am häufigsten iatrogen nach Krebstherapien erworben. Meist gehören die radikale Lymphadenektomie sowie die Radiotherapie als essenzielle Bestandteile zum Therapiekonzept bei Krebserkrankungen. Diese sind stark assoziiert mit dem Extremitätenlymphödem. Resezierende Verfahren sollten nur im Endstadium der Erkrankung evaluiert werden, wobei die Liposuktion als Ausnahme und weniger invasives resezierendes Verfahren zu einer effektiven Gewebereduktion führen kann. Lymphovenöse Anastomosen und der mikrovaskuläre Lymphknotentransfer haben das experimentelle Stadium verlassen und stellen für ein korrekt auserwähltes Patientenkollektiv echte therapeutische Optionen dar, um die Hautqualität zu verbessern und das Fortschreiten der Erkrankung aufzuhalten. Die Kosten dafür werden zurzeit nur teilweise auf Antrag von den Krankenkassen übernommen. Für Betroffene eröffnen sich mit den mikrochirurgischen Methoden neue Aussichten auf ein besseres Leben. Um das geeignete Patientenkollektiv noch genauer zu definieren und die guten Resultate zu bestätigen, sind prospektive Studien mit höheren Fallzahlen und Langzeitstudien notwendig.